Tehran University of Medical Sciences Frontiers in Emergency Medicine 2717-3593 4 2s 2020 05 26 e51 e51 Pooya Payandemehr Prehospital and Hospital Emergency Research Center, Tehran University of Medical Sciences, Tehran, Iran Morteza Azhdarzadeh Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Hooman Bahrami-Motlagh Radiology Department, Loghman Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran Azar Hadadi Department of Infectious Diseases, Tehran University of Medical Sciences, Tehran, Iran Farhad Najmeddin Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Shaghayegh Shahmirzaei Trauma and Surgery Research Center, Sina hospital, Tehran University of Medical sciences, Tehran, Iran Marzieh Pazoki Department of Pulmonary Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran Mehran Sotoodehnia Prehospital and Hospital Emergency Research Center, Tehran University of Medical Sciences, Tehran, Iran Reza Rahimian McGill Group for Suicide Studies, Douglas Mental Health University Institute, McGill University, Montreal, QC, Canada 2020 05 26 Introduction: Since December 2019, an outbreak of Covid-19 has caused growing concern in multiple countries. Researchers around the world are working to find a treatment or a vaccine for Covid-19 and different treatment approaches have been tested in this regard.  Objective: This study was designed and conducted to assess the possible efficacy of Interferon beta-1a as a safe and efficient candidate for Covid-19 treatment.  Methods: This is an investigator-initiated, open-label, single-arm clinical trial. Twenty patients with suspected Covid-19, who were admitted to Sina hospital in Tehran, Iran, with moderate to severe symptoms, from 6 to 10 March, 2020, were enrolled. Patients were treated with antiviral and hydroxychloroquine combination therapy, along with subcutaneous Interferon beta-1a for 5 consecutive days. Baseline characteristics and findings during the course of admission and 5 days after discharge were recorded for all the patients.  Results: In total, 20 patients with suspected Covid-19 were included in this study, 12 (60%) of which were male. The median (Interquartile (IQ) range) of patients’ age was 55.5 (43-63.5). The most common symptom of the patients at onset of disease was fever. The median (IQ range) of duration of hospital stay was 5.0 (3-6) days. Only 2 cases were admitted to ICU. At the time of follow-up, 15 (94%) patients reported that they generally felt good and had oral tolerance, 1 patient had suffered from dyspnea, 5 patients had suffered from cough, none of them had experienced fever and no case of re-admission or death was reported after discharge.  Conclusions: Results of the current study are in favor of using Interferon beta-1a in addition to recommended antiviral treatment in Covid-19 patients. https://fem.tums.ac.ir/index.php/fem/article/view/454 https://fem.tums.ac.ir/index.php/fem/article/download/454/307